Profitability
Weight: 25%
D-
30
- 5yr Avg ROIC -15.0%
- Operating Margin Trend +101.36 pp/yr
TBPH
Theravance Biopharma Inc
AlphaQuality composite grade, weighted for platform & compounding fcf businesses.
⚠ 3 of the last 5 fiscal years showed negative net income — AlphaQuality will not grade above F for persistent unprofitability in a platform & compounding fcf business.
Grade overrides the 30.0 pillar composite — hard gates always win.
Capital Efficiency
Weight: 15%
A+
99
- 5yr Avg ROE 43.8%
- 5yr Share-Count CAGR -3.7%
Growth Quality
Weight: 25%
B
71
- 5yr Revenue CAGR 8.4%
- Revenue-Growth Years (5) 3/5
Cash Generation
Weight: 20%
C-
45
- 5yr FCF Margin -119.0%
- 5yr FCF/NI Conversion 1.02x
Balance Sheet
Weight: 10%
A
88
- Net Debt / EBITDA -1.75x
- Interest Coverage (EBIT/Int) 53.52x
- Altman Z-Score 2.39
Stability
Weight: 5%
B
70
- Negative-Revenue Years (5) 2/5
- Piotroski F-Score 7
Guru Flow
Curated superinvestor sentiment — not part of the AlphaQuality grade.1 of 2 gurus held; 1 added; 2 full exits.
- Holders
- 1 -1
- Avg Δ position
- +24.2%
- New buys
- 0
- Full exits
- 2
- Greenblatt sold -100%
- Wood sold -100%
- Cooperman increased +24%